Avastin and Tamiflu quash Roche cash but sales up by 9% in 2010
This article was originally published in Scrip
Executive Summary
Roche has been forced to cut its guidance estimates for Avastin sales, following the US FDA's recent decision that the drug is neither safe nor effective in breast cancer, leading to disappointing 2011 revenue and EPS guidance.